CJC-1295 (Mod GRF 1-29, molecular weight 3367.97 Da) is a 29-amino acid peptide analogue of human GHRH(1-29) carrying four amino acid substitutions that confer resistance to enzymatic cleavage: Tyr-{D-Ala}-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. The substitutions at D-Ala2 (prevents DPP-4 cleavage), Gln8, Ala15, and Leu27 stabilize the secondary alpha-helix and prevent oxidative deamidation in aqueous solution.

Ipamorelin (molecular weight 711.86 Da) is a synthetic pentapeptide with the sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2. It features an alpha-aminoisobutyric acid (Aib) at position 1 and unnatural aromatic residues (D-2-naphthylalanine and D-phenylalanine) at positions 3 and 4, which impart exceptional chemical stability and high-affinity steric complementarity for the ghrelin/growth hormone secretagogue receptor (GHS-R1a).

When co-formulated as a lyophilized blend, the two distinct peptide chains maintain independent solution dynamics without covalent interaction, co-aggregating in 1:1 or specific stoichiometric ratios that dissolve cleanly in standard bacteriostatic water.

Anterior pituitary somatotrophs feature two distinct cell-surface receptors that control growth hormone synthesis and exocytosis: the GHRH receptor (GHRH-R) and the growth hormone secretagogue receptor (GHS-R1a).

CJC-1295 binds to the GHRH-R, activating stimulatory G-protein Gs-alpha, which stimulates adenylate cyclase to convert ATP into cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB to stimulate de novo GH gene transcription and opens voltage-gated L-type Ca2+ channels.

Simultaneously, Ipamorelin binds to GHS-R1a, coupling through Gq/11 to activate phospholipase C (PLC). PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to receptors on the endoplasmic reticulum, prompting an immediate efflux of stored Ca2+ into the cytoplasm.

The convergence of PKA phosphorylation (from CJC-1295) and rapid intracellular Ca2+ elevation (from Ipamorelin) triggers the SNARE-mediated fusion of pre-docked GH secretory granules with the plasma membrane, generating a physiological pulsatile GH release that is substantially greater than the sum of either agent administered alone.

Earlier-generation ghrelin secretagogues—including GHRP-6, GHRP-2, and hexarelin—exhibit cross-reactivity with hypothalamic and pituitary receptors, frequently triggering unwanted elevations in adrenocorticotropic hormone (ACTH), cortisol, and prolactin.

Raun et al. (Eur J Endocrinol 1998) demonstrated that Ipamorelin displays near-absolute receptor selectivity for the GHS-R1a. In in vitro pituitary cell perifusion experiments and in vivo swine and rodent models, Ipamorelin stimulated robust GH release without inducing any statistically significant changes in plasma ACTH, cortisol, aldosterone, or prolactin, even at supramaximal concentrations up to 1,000 nM.

This high selectivity ensures that the CJC-1295 + Ipamorelin co-protocol stimulates purely the somatotrophic axis, avoiding the fluid retention, hypercortisolemia, and gynecomastia associated with non-selective GH secretagogues.

In clinical pharmacokinetic investigations (Teichman et al., J Clin Endocrinol Metab 2006), administration of GHRH analogues and selective secretagogues produced dose-dependent, sustained elevations in mean 24-hour growth hormone area under the curve (GH-AUC) and circulating insulin-like growth factor-1 (IGF-1) levels.

Serum IGF-1 levels increased by 45% to 80% following 7 to 14 days of protocol administration, accompanied by parallel increases in insulin-like growth factor binding protein-3 (IGFBP-3), verifying that the released GH possesses full biological activity in stimulating hepatic somatomedin synthesis.

Importantly, because the pulsatile secretory pattern is preserved and somatotroph responsiveness remains subject to hypothalamic somatostatin (SRIF) negative feedback, the risk of developing acromegaly-like soft tissue hyperplasia or pathological insulin resistance is drastically attenuated compared to continuous exogenous recombinant human GH (rhGH) administration.

CJC-1295 and Ipamorelin are frequently provided either as separate vials (e.g., 2 mg CJC-1295 No DAC vial + 5 mg Ipamorelin vial) or as a pre-mixed co-lyophilized blend (e.g., 5 mg / 5 mg or 10 mg / 10 mg vial).

Reconstitution calculation for a 5 mg / 5 mg blend vial (10 mg total net peptide): adding 2.5 mL of Bacteriostatic Water USP (0.9% benzyl alcohol) yields a concentration of 2.0 mg/mL of CJC-1295 and 2.0 mg/mL of Ipamorelin (200 mcg of each peptide per 0.10 mL).

Syringe calibration on a standard U-100 syringe (100 units = 1.0 mL; 1 unit = 0.01 mL = 20 mcg of each peptide): a standard research dose of 100 mcg CJC-1295 + 100 mcg Ipamorelin corresponds to 5 units (0.05 mL); a 200 mcg / 200 mcg dose corresponds to 10 units (0.10 mL).

Solvation instructions: introduce diluent gently down the inside glass wall. Invert slowly until complete optical dissolution occurs within 60 seconds. Storage: Solid lyophilate is stable at -20°C for up to 36 months. Reconstituted aqueous solution with 0.9% benzyl alcohol must be stored refrigerated at 2°C–8°C away from light, maintaining chemical stability for up to 28 days.